ANDA 209425, held by Apotex. Carfilzomib.
As of Nov 16, 2026, ANDA 209425 (Carfilzomib), held by Apotex, was first approved by FDA on Mar 16, 2020, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 16, 2020 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Carfilzomib60MG/VIAL · powder;intravenous | Carfilzomib | Discontinued |
| Nov 24, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 24, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 24, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 24, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 16, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters